It was 1978, and a group of prominent biologists had just gotten together to form a new company called Biogen — founded on the back of Nobel Prize-winning discoveries that promised a world in which scientists could clone just about any molecule they could find in nature.
A year later, the company had figured out how to clone interferon, a signaling protein that could treat a form of leukemia. Its scientists went on to develop a hepatitis B vaccine. And, over the intervening years, the Cambridge, Mass.-based Biogen could proudly and consistently claim to be a pillar of American biotech.
About the Author Reprints
After the announcement of earnings, in the past one week, the stock has increased quite well. Hope Biogen comes up with new drugs or acquisitions in the near future. https://news.alphastreet.com/biogens-quarterly-profit-jumps-but-stock-falls/